1 / 75

THE DEVELOPMENT OF B-LYMPHOCYTES

THE DEVELOPMENT OF B-LYMPHOCYTES. STAGES IN LIFE CYCLE OF B-LYMPHOCYTES. Stage 1 Maturation in bone marrow with development of functional receptors Stage 2 Testing for and elimination of self-reactive receptors Stage 3 Mature naïve cells move to secondary lymphoid tissues Stage 4

ulfah
Download Presentation

THE DEVELOPMENT OF B-LYMPHOCYTES

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. THE DEVELOPMENT OF B-LYMPHOCYTES

  2. STAGES IN LIFE CYCLE OF B-LYMPHOCYTES • Stage 1 • Maturation in bone marrow with development of functional receptors • Stage 2 • Testing for and elimination of self-reactive receptors • Stage 3 • Mature naïve cells move to secondary lymphoid tissues • Stage 4 • Antigen contact with differentiation into plasma cells and memory cells

  3. B-CELL DEVELOPMENT IN BONE MARROW • Stages are defined by rearrangement and expression of IG genes • Early Pro-B cells • Earliest cells in B-cell lineage • Rearrangement of variable domain of heavy chains • D to J • Late Pro-B cell • Rearrangement of variable domain of heavy chains • V to DJ

  4. B-CELL DEVELOPMENT IN BONE MARROW • Large Pre-B cell • M expressed on cell surface along with surrogate light chains and signal transduction molecules • Pre-B cell receptor • Small Pre-B cell • Pre-B cell receptor not present • Most M chains inside cell • Light chain rearrangement begins

  5. B-CELL DEVELOPMENT IN BONE MARROW • Immature B-cell • Heavy and light chains assembled and transported to surface as IgM receptor complex • Randomness of gene rearrangements leads to self-reactive B-cells • Mature B-cell • IgD expressed on cell surface • Called naïve B-cells

  6. Figure 4-4

  7. B-CELL DEVELOPMENT IN BONE MARROW • Development depends on non-lymphoid stromal cells • Function of stromal cells • Specific contact through cell adhesion molecules (CAM’s) • VCAM-1 to VLA-4 on early pro-B cells • Produce growth factors for bound B-cells • Stem cell factor (SCF) • Interleukin-7 (IL-7) • Growth factors • Stem cell factor stimulates (G/P) of Early pro-B cells • Interleukin-7 stimulates (G/P) of Late pro-B and L/S pre-B cells

  8. GENE REARRANGEMENTS AND B-CELL SURVIVAL • Gene rearrangement process is imprecise and classified as • Unproductive • Not translated into IG chain • B-cell dies • Productive • Translated into IG chain • Development proceeds • Immunoglobulin loci • Each B-cell has 2 copies on homologous chromosomes • Rearrangements made on both

  9. PROTEINS INVOLVED IN REARRANGEMENT AND EXPRESSION OF IG GENES • Several categories of specialized proteins are required • Lymphoid specific recombination • RAG-1 and RAG-2 • N-nucleotide addition • TdT • Surrogate light chains • Lambda5 and VpreB • Signal transduction • IG-alpha, IG-beta, CD45 and Btk • Transcription factors • EBF and Oct-2

  10. SIGNAL TRANSDUCTION AND BRUTON’S TYROSINE KINASE (BTK) • Bruton’s tyrosine kinase (Btk) • Encoded by gene on X chromosome • Essential for B cell maturation • Mutation in gene • B cells maturation stops at pre-B cell stage • Results in immunodeficiency called • Bruton’s X-linked agammaglobulinemia • Immunodeficiency results in recurrent sinopulmonary infections with • Streptococcus pneumoniae • Haemophilus influenzae

  11. POPULATIONS (SUBSETS) OF B CELLS • B-1 cells (minor subset) • Develop early in embryonic life with unknown origin • Express CD5 (CD5 B cells) • Self-renewing • Primary location is body cavities (pleural / peritoneal) • Produce polyspecific antibodies • B-2 cells (major subset) • Develop after birth • Do not express CD5 glycoprotein • Replaced from bone marrow • Primary location is lymphoid organs • Produce highly specific antibodies

  12. NEGATIVE SELECTION AND FURTHER DEVELOPMENT OF B CELLS • Self reactive immature B cells are either • Eliminated or inactivated • IgM receptor may react with • Cell surface or soluble self antigens • Reactions with cell surface antigens • Induced to commit suicide by apotosis • Clonal deletion • Reactions with soluble antigens • Rendered unresponsive (anergic) to antigen • Maturation continues with reduced surface IgM

  13. SELECTION AND FURTHER DEVELOPMENT OF B CELLS • B cells leave bone marrow and circulate between blood and secondary lymphoid tissues • Secondary lymphoid tissue contains primary lymphoid follicles • Primary lymphoid follicle • Area where B cells congregate in association with specialized stromal cells (follicular dendritic cells) • Passage through primary lymphoid follicle and contact with follicular dendritic cells (FDC) necessary for survival • Few days with no passage • 3 to 8 weeks with passage

  14. CIRCULATION OF B CELLS THROUGH SECONDARY LYMPHOID TISSUES (LYMPH NODES) • Chemokines attract B cells to leave blood and enter cortex of lymph node via high endothelial venule (HEV) • Chemokines attract B cells to lymph node and primary lymphoid follicle • No encounter with antigen • B cells leave node via efferent lymphatic vessel • Anergic B cells detained in T cell area • Induced to commit suicide by apoptosis

  15. B CELL ENCOUNTER WITH ANTIGEN IN SECONDARY LYMPHOID TISSUES • Encounter with antigen takes place in T cell area of lymph node cortex • Antigen reached lymph node from infected tissue via afferent lymphatic vessel • B cell is activated by CD4 T-cell in T-cell area • Activated B cells • Migrate to medulla area and differentiate into plasma cells • Migrate to primary follicle to form germinal center • Migrate to medulla or bone marrow and complete differentiation into plasma cells • Develop into memory B cells

  16. B-LYMPHOCYTE TUMORS • Caused by mutations in genes that regulate cell growth • Genes regulating cell growth • Proto-oncogenes • Promotes cell growth • Tumor suppressor genes • Inhibits cells growth • Mutations in growth regulating genes • Transformation into oncogenes (cancer causing genes)

  17. B LYMPHOCYTE TUMORS • Represents uncontrolled growth of single transformed B cell • Associated with all stages of development • Tumors retain characteristics of cell type and location • Hodgkin’s Lymphoma • Germinal center B cell in lymphoid tissue • Multiple myeloma • Plasma cell in bone marrow • Waldenstrom’s macroglobulinemia • IgM secreting B lymphocyte in lymphoid tissue • Burkitt’s lymphoma • Resembles germinal center B cell in lymphoid tissue

  18. Figure 4-19

  19. HODGKIN’S DISEASE (LYMPHOMA) • Hodgkin’s disease is a type of lymphoma • Two types of lymphoma • Hodgkin’s disease • Non-Hodgkin’s lymphoma (NHL) • Two main types of Hodgkin’s disease • Classical (95%) • Nodular lymphocyte predominance (5%) • Disease most often starts in lymph nodes of upper body • Chest, neck or under the arms

  20. HODGKIN’S DISEASE (LYMPHOMA) • Cause is not known but there are risk factors • Epstein-Barr Virus (EBV) infection • Geography • United States, Canada, northern Europe • Family history • Identical twin (very high) • Approximately 8,000 new cases each year in US • Cancer cells of HD are unique • Reed-Sternberg cells

  21. WALDENSTROM’S MACROGLOBULINEMIA • Indolent, non-Hodgkin’s lymphoma (NHL) • Classified as • Monoclonal gammopathy • Cancer cells • Features of B-cells and plasma cells • Lymphoplasmacytoid • Located primarily in bone marrow • Produce large amounts of monoclonal protein (antibody) • IgM • Approximately 1,500 new cases each year in US

  22. MULTIPLE MYELOMA • Aggressive, non-Hodgkin lymphoma • Classified as • Monoclonal gammopathy • Cancer cells • Abnormal plasma cells (myeloma cells) • Located primarily in bone marrow • Produce monoclonal proteins (antibody) • IgG, IgA, free kappa or lambda light chains • Approximately 20,000 cases in US for 2008

  23. BURKITT’S LYMPHOMA • B cell tumor with 2 forms • Endemic (African) • Facial tumors • Strongly associated with EBV infection • Nonendemic (Sporadic) • Abdominal tumors • Characteristic translocation • MYC proto-oncogene on chromosome 8 to IG genes • Chromosome 14 (90%) • Chromosomes 2 and 22 (10%) • MYC protein • Normally regulates cell division • Control is lost following translocation to IG gene

  24. CASE STUDY – 21 YEAR OLD MALE • 21 year old WM presents with • Fever (102 F) • Sore throat • Moderate malaise, myalgia and fatigue • Difficulty in swallowing • H and P • Healthy and sexually active • Bilateral anterior and posterior cervical lymphadenopathy • Pharyngeal inflammation • Mild splenomegaly and no jaundice

  25. CASE STUDY – 21 YEAR OLD MALE • Admitted to MC and administered • Penicillin G • Prednisone • Valacyclovir • Laboratory tests • CBC with diff • Liver function tests • Monospot test (Heterophile antibody) • Erythrocyte sedimentation rate (ESR) • Group A streptococcus antigen

  26. CASE STUDY – 21 YEAR OLD MALE • CBC with diff • WBC 12.5 [4.8-10.8] K/uL • RBC 4.0 [3.93-5.22] M/uL • Platelets 250 [150-450] K/uL • Hemoglobin 14.0 [11.2-15.7] g/dL • Hematocrit 40 [34.1-44.9] % • Neutrophils 45 [40-74] % • Lymphocytes 55 [15-47] % • Atypical lymphocytes 18 % • Monocytes 12 [0-12] %

  27. REACTIVE (ATYPICAL) LYMPHOCYTES • Larger in size • Up to 30 um in diameter • More cytoplasm • Less dense nuclear chromatin • Irregular shaped nucleus • Nucleous may be present • Periphery of cell show “scalloped edge”

  28. CASE STUDY – 21 YEAR OLD MALE • Liver function tests • ALT 130 [19-55] U/L • AST 112 [15-37] U/L • Alk phos 150 [50-136] U/L • ESR 40 [0-30] mm/hr • GAS antigen Negative [Negative] • Monospot test Positive [Negative]

  29. CASE STUDY – 21 YEAR OLD MALE • Patient discharged after 36 hours • Treatment • NSAID • Recommendations • Avoid sports • Avoid alcohol

More Related